Aytu BioPharma, Inc (AYTU) income statement
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.00 (0.00%)
Close on Nov 18, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma, Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 64.0%
- Operating margin
- -14.4%
- Net margin
- -24.8%
- Return on equity, FY2026
- -52.6%
Financial strength
- Current ratio
- 1.13
- Debt to equity
- 0.31
- Debt to assets
- 10.4%
- Cash to current liabilities
- 48.1%
Valuation
- P/E ratio
- –
- Price to sales
- 0.50
- Price to book
- 0.82
- Dividend yield
- –
See a number that looks wrong?